Paper Details

  1. Home
  2. Paper Details

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Author: AlexanderG J, BrahmJ, DanielsH M, EddlestonA L, FaganE A, SmithH M, WilliamsR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 46 male chronic hepatitis B carriers found that interferon treatment led to seroconversion from HBeAg to anti-HBe in 6 out of 23 patients.
Paper Details　
Original Abstract of the Article :
46 male chronic hepatitis B virus (HBV) carriers with active viral replication were randomised, with stratification for histology and sexual preference, to receive six months' lymphoblastoid interferon or no therapy. After nine to eighteen months' follow-up, HBeAg was no longer detectable and anti-H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(87)92735-8

データ提供：米国国立医学図書館（NLM）

Interferon Therapy: A Potential Pathway to Hepatitis B Virus Clearance

The realm of [hepatology] is constantly evolving, and this study explores the effectiveness of interferon therapy in combating chronic hepatitis B virus (HBV) infection. The researchers conducted a [randomized controlled trial] with 46 male HBV carriers, evaluating the impact of six months of lymphoblastoid interferon therapy. The study focused on the clearance of HBsAg, a key marker of HBV infection. Their findings showed that interferon therapy resulted in the loss of HBsAg in a significant number of patients, demonstrating its potential to clear HBV. This study provides valuable insights into the potential of interferon therapy as a treatment option for HBV infection.

Interferon's Role in HBV Clearance: A Glimpse of Hope

The study's findings, showing that interferon therapy led to HBsAg loss in a substantial number of patients, offer a ray of hope for individuals battling chronic HBV infection. This suggests that interferon therapy could potentially be a valuable tool in the fight against HBV, paving the way for a healthier future for those affected by this viral disease. The study also highlights the importance of monitoring liver function during interferon therapy, as increased liver enzyme levels may precede HBsAg loss.

Understanding the Landscape of Hepatitis B Virus Infection

Imagine the hepatitis B virus as a persistent desert wind, gradually eroding the health of the liver. Interferon therapy, like a powerful storm, can disrupt this destructive force, potentially leading to the clearance of the virus. While this study offers promising results, continued research is essential to fully understand the nuances of interferon therapy and its long-term effects on HBV infection.

Dr. Camel's Conclusion

As a researcher who has traversed the vast desert of infectious diseases, I'm always intrigued by the relentless battle between our bodies and viruses. This study on the potential of interferon therapy in clearing HBV infection is a testament to the ongoing efforts to combat these invisible foes. The study's findings, while encouraging, underscore the importance of ongoing research to optimize treatment strategies and improve the lives of individuals affected by chronic HBV.

Date :
  1. Date Completed 1987-08-12
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

2885573

DOI: Digital Object Identifier

10.1016/s0140-6736(87)92735-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.